Cefazolin injection reduces the rate of postoperative endophthalmitis

Article

Administering cezafolin injections after cataract surgery reduces the rate of postoperative endophthalmitis.

Administering cefazolin injections after cataract surgery reduces the rate of postoperative endophthalmitis, claims a study in the journal Bio Med Central.

Dr Pedro Romero-Aroca et al., Ophthalmology Service. Hospital Universitari Sant Joan, IISPV, Universidad Rovira i Virgili, Reus, Spain, conducted a prospective, observational study on 25001 patients.

All participants were divided into two groups: Group 1, consisting of 11696 patients, was operated on between January 2002 and December 2002 and Group 2, with 13305 patients, was administered a 1 mg/0.1 bolus of intracameral cefazolin between January 2003 and December 2009.

Of the patients studied, there were 76 cases of endophthalmitis in Group 1, compared to 7 in Group 2. Postoperative endophthalmitis rate decreased from 0.63% to 0.05% after a cefazolin. The relative risk of endophthalmitis in Group 1, compared to Group 2, was 11.45.

Intracameral bolus injections of cefazolin after cataract surgery significantly reduce the rate of postoperative endophthalmitis.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.